Telcagepant is a new oral treatment for migraine
| العنوان: | Telcagepant is a new oral treatment for migraine |
|---|---|
| المؤلفون: | Sheila A Doggrell |
| المصدر: | Expert Opinion on Pharmacotherapy. 10:1523-1526 |
| بيانات النشر: | Informa Healthcare, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Pharmacology, Telcagepant, Photophobia, business.industry, Nausea, Zolmitriptan, General Medicine, Triptans, Calcitonin gene-related peptide, medicine.disease, Phonophobia, Migraine, Anesthesia, medicine, Pharmacology (medical), medicine.symptom, business, medicine.drug |
| الوصف: | Background: Migraine is a common cause of disability. Many subjects (30 – 40%) do not respond to the 5-HT1B/1D agonists (the triptans) commonly used in the treatment of migraine attacks. Calcitonin gene-related protein (CGRP) receptor antagonism is a new approach to the treatment of migraine attacks. Objectives/methods: This evaluation is of a Phase III clinical trial comparing telcagepant, an orally active CGRP receptor antagonist, with zolmitriptan in subjects during an attack of migraine. Results: Telcagepant 300 mg has a similar efficacy to zolmitriptan in relieving pain, phonophobia, photophobia, and nausea. Telcagepant was better tolerated than zolmitriptan. Conclusions: The initial Phase III clinical trial results with telcagepant are promising but several further clinical trials are needed to determine the place of telcagepant in the treatment of migraine attacks. |
| تدمد: | 1744-7666 1465-6566 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::358297fa89fe83a1435be2ad7cf7548dTest https://doi.org/10.1517/14656560902980236Test |
| رقم الانضمام: | edsair.doi...........358297fa89fe83a1435be2ad7cf7548d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447666 14656566 |
|---|